DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition

NCT05770102 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Malignancy
Malignant Neoplasm
Lymphoproliferative Disorders
Neoplasms by Histologic Type
Neoplasms by Site
Cancer
Colorectal Neoplasms
Endometrial Neoplasms
Melanoma
Solid Tumours

Interventions

DRUG: Atezolizumab

Sponsor

Cancer Research UK

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]